TAVI in nonagenarians, what do we know so far?

Transcatheter aortic valve implantation (TAVI) has become a widely used therapeutic strategy to treat symptomatic severe aortic stenosis. Certain randomized clinical trials available have already described the prognostic benefit of this technique in elderly patients with high or very high surgical r...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pablo Díez-Villanueva, Fernando Rivero
Formato:	article
Lenguaje:	EN ES
Publicado:	Permanyer 2021
Materias:	Medicine R
Acceso en línea:	https://doaj.org/article/5c6f1b4ee0ba499fb09a81b330496ece
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5c6f1b4ee0ba499fb09a81b330496ece
record_format	dspace
spelling	oai:doaj.org-article:5c6f1b4ee0ba499fb09a81b330496ece2021-11-16T10:24:46ZTAVI in nonagenarians, what do we know so far?10.24875/RECICE.M210002282604-7322https://doaj.org/article/5c6f1b4ee0ba499fb09a81b330496ece2021-11-01T00:00:00Zhttps://recintervcardiol.org/en/index.php?option=com_content&view=article&id=721https://doaj.org/toc/2604-7322Transcatheter aortic valve implantation (TAVI) has become a widely used therapeutic strategy to treat symptomatic severe aortic stenosis. Certain randomized clinical trials available have already described the prognostic benefit of this technique in elderly patients with high or very high surgical risk. Also, when implanted via transfemoral access, it has proven non-inferior or even superior compared to surgical aortic valve replacement in low- and intermediate-risk patients. Therefore, the current recommendations support its use in elderly patients with severe aortic stenosis regardless of their surgical risk.1 However, since it is an age-related heart valve disease without an effective medical therapy yet, the prevalence of severe aortic stenosis has been growing parallel to life expectancy. As a matter of fact, this disease has huge repercussions in the patients’ survival rate and quality of life.2 Consequently, nonagenarian patients with severe aortic stenosis are a group in continuous expansion, and, to this date, the best way to treat them is still under discussion. Since most of these patients have traditionally been misrepresented in the clinical trials and there are registries with good results but a possible selection bias, the decision to treat these patients with TAVI is still challenging and is made on an individual...Pablo Díez-VillanuevaFernando RiveroPermanyerarticleMedicineRENESREC: Interventional Cardiology (English Ed.), Vol 3, Iss 4, Pp 245-246 (2021)
institution	DOAJ
collection	DOAJ
language	EN ES
topic	Medicine R
spellingShingle	Medicine R Pablo Díez-Villanueva Fernando Rivero TAVI in nonagenarians, what do we know so far?
description	Transcatheter aortic valve implantation (TAVI) has become a widely used therapeutic strategy to treat symptomatic severe aortic stenosis. Certain randomized clinical trials available have already described the prognostic benefit of this technique in elderly patients with high or very high surgical risk. Also, when implanted via transfemoral access, it has proven non-inferior or even superior compared to surgical aortic valve replacement in low- and intermediate-risk patients. Therefore, the current recommendations support its use in elderly patients with severe aortic stenosis regardless of their surgical risk.1 However, since it is an age-related heart valve disease without an effective medical therapy yet, the prevalence of severe aortic stenosis has been growing parallel to life expectancy. As a matter of fact, this disease has huge repercussions in the patients’ survival rate and quality of life.2 Consequently, nonagenarian patients with severe aortic stenosis are a group in continuous expansion, and, to this date, the best way to treat them is still under discussion. Since most of these patients have traditionally been misrepresented in the clinical trials and there are registries with good results but a possible selection bias, the decision to treat these patients with TAVI is still challenging and is made on an individual...
format	article
author	Pablo Díez-Villanueva Fernando Rivero
author_facet	Pablo Díez-Villanueva Fernando Rivero
author_sort	Pablo Díez-Villanueva
title	TAVI in nonagenarians, what do we know so far?
title_short	TAVI in nonagenarians, what do we know so far?
title_full	TAVI in nonagenarians, what do we know so far?
title_fullStr	TAVI in nonagenarians, what do we know so far?
title_full_unstemmed	TAVI in nonagenarians, what do we know so far?
title_sort	tavi in nonagenarians, what do we know so far?
publisher	Permanyer
publishDate	2021
url	https://doaj.org/article/5c6f1b4ee0ba499fb09a81b330496ece
work_keys_str_mv	AT pablodiezvillanueva taviinnonagenarianswhatdoweknowsofar AT fernandorivero taviinnonagenarianswhatdoweknowsofar
_version_	1718426549238104064

TAVI in nonagenarians, what do we know so far?

Ejemplares similares